NOVA — Nova Mentis Life Science Balance Sheet
0.000.00%
- CA$1.48m
- CA$1.52m
Annual balance sheet for Nova Mentis Life Science, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2019 December 31st | R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 0.847 | 2.14 | 0.219 | 0.267 | 0.008 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.007 | 0.017 | 0.07 | 0.008 | 0.007 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Current Assets | 0.88 | 2.58 | 0.328 | 0.282 | 0.02 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.03 | 0.023 | 0.018 | 0.014 | 0.011 |
Long Term Investments | |||||
Total Assets | 6.58 | 3.05 | 0.881 | 0.297 | 0.031 |
Payable / Accrued | |||||
Notes Payable / Short Term Debt | |||||
Total Current Liabilities | 0.325 | 0.383 | 0.422 | 0.255 | 0.842 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Liabilities | 0.325 | 0.383 | 0.422 | 0.255 | 0.842 |
Common Stock | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 6.26 | 2.66 | 0.459 | 0.041 | -0.811 |
Total Liabilities & Shareholders' Equity | 6.58 | 3.05 | 0.881 | 0.297 | 0.031 |
Total Common Shares Outstanding |